← All trials
NCT01285778
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- Dec 1, 2015
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 58
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Espanol Multidisciplinario del Cancer DigestivoLead sponsor
- University of BarcelonaOverall official - principal investigator
- Hospital Infanta SofiaOverall official - principal investigator
- Hospital de MataróOverall official - principal investigator
- Hospital Son LlatzerOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Hospital Virgen Blanca (León)Overall official - principal investigator
- Centro Oncológico de GaliciaOverall official - principal investigator
- Hospital de ManisesOverall official - principal investigator
- University of SalamancaOverall official - principal investigator
- University of ZaragozaOverall official - principal investigator
- AmgenCollaborator
- Trial Form Support S.L.Collaborator
- Clinica Universidad de NavarraOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad Autonoma de MadridStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.